Posted by Michael Wonder on 20 Dec 2016
Proposal to maintain full subsidy for gefitinib (Iressa) from 1 April 2017
20 December 2016 - PHARMAC is seeking feedback on a proposal to amend the contractual terms of funding for gefitinib (Iressa) through a provisional agreement with AstraZeneca, which would result in gefitinib remaining fully funded at its current subsidy from 1 April 2017.
This would in effect reverse a previous decision to reduce the subsidy for gefitinib from 1 April 2017, as notified on 5 December 2016, meaning that gefitinib would remain fully funded.
